Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1073/pnas.1703931114 http://scihub22266oqcxt.onion/10.1073/pnas.1703931114 C5402464!5402464!28377514     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Proc+Natl+Acad+Sci+U+S+A 2017 ; 114 (16): 4153-8 Nephropedia Template TP {{tp|p=28377514|t=2017. SMARCE1 is required for the invasive progression of in situ cancers |pdf=|usr=}}{{28377514}} gab.com Text SMARCE1 is required for the invasive progression of in situ cancers JO: Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=28377514 #FOAvip More than half of ductal carcinoma in situ (DCIS) lesions will never progress to invasive breast cancers. However, the factors that drive invasion are not well understood. Our findings establish SMARCE1 as a clinically relevant factor that promotes the invasive progression of early-stage breast cancers. SMARCE1 drives invasion by serving as a master regulator of genes encoding proinvasive ECM and proteases required to degrade basement membrane. In functional studies in 3D cultures and animal models, SMARCE1 is dispensable for tumor growth but is required for the invasive and metastatic progression of cancers. In patients, SMARCE1 expression specifically identifies early-stage breast, lung, and ovarian cancers that are likely to eventually progress and metastasize. Twit Text FOAVip SMARCE1 is required for the invasive progression of in situ cancers ????Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=28377514 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28377514 #FOAvip English Wikipedia <ref>{{Cite pmid|28377514}}</ref> SMARCE1 is required for the invasive progression of in situ cancers #MMPMID28377514 Sokol ES; Feng YX; Jin DX; Tizabi MD; Miller DH; Cohen MA; Sanduja S; Reinhardt F; Pandey J; Superville DA; Jaenisch R; Gupta PB Proc Natl Acad Sci U S A 2017[Apr]; 114 (16): 4153-8 PMID28377514show ga More than half of ductal carcinoma in situ (DCIS) lesions will never progress to invasive breast cancers. However, the factors that drive invasion are not well understood. Our findings establish SMARCE1 as a clinically relevant factor that promotes the invasive progression of early-stage breast cancers. SMARCE1 drives invasion by serving as a master regulator of genes encoding proinvasive ECM and proteases required to degrade basement membrane. In functional studies in 3D cultures and animal models, SMARCE1 is dispensable for tumor growth but is required for the invasive and metastatic progression of cancers. In patients, SMARCE1 expression specifically identifies early-stage breast, lung, and ovarian cancers that are likely to eventually progress and metastasize. äSMARCE1 is required for the invasive progression of in situ cancers (epmc).pdf DeepDyve Pubget Overpricing